China: The Next Pharmacy of the World?

Feng-Chi Chen

doi:10.1016/j.tips.2018.07.004

China: The Next Pharmacy of the World?

Trends Pharmacol Sci. 2018 Oct;39(10):843-848. doi: 10.1016/j.tips.2018.07.004. Epub 2018 Aug 8.

Author

Feng-Chi Chen¹

Affiliation

¹ Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, 35053, Taiwan; Department of Biological Science and Technology, National Chiao-Tung University, Hsinchu City, 30010, Taiwan; School of Dentistry, China Medical University, Taichung City, 40402, Taiwan; School of Law, National Chiao-Tung University, Hsinchu City, 30010, Taiwan. Electronic address: fcchen@nhri.org.tw.

PMID: 30098798
DOI: 10.1016/j.tips.2018.07.004

Abstract

The manufacturing success in China has not yet radiated to the pharmaceutical sector. Recently, China released a policy guideline to foster its follow-on drug industry, revealing its ambition to become a great power in the field. Here, I briefly discuss how this guideline may change the industry landscape, and its associated challenges and opportunities.

Keywords: China; biosimilar; follow-on drug; generic; government policy; intellectual property.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biosimilar Pharmaceuticals
China
Drug Industry*
Drugs, Generic
Government
Health Policy
Intellectual Property

Substances

Biosimilar Pharmaceuticals
Drugs, Generic